Drug intelligence / Profile preview

optoRET

Development stage: Preclinical
Lead developer: KAIST
Modality: Gene Therapies

Overview

optoRET is an optogenetic tool designed for the ligand-independent, light-controlled activation of the RET (REarranged during Transfection) receptor tyrosine kinase. Developed by researchers at the Korea Advanced Institute of Science and Technology (KAIST) and the Institute for Basic Science (IBS), optoRET is engineered by fusing the cytosolic domain of human RET with a blue-light-inducible homo-oligomerizing protein. Upon blue light illumination, optoRET undergoes clustering and autophosphorylation, recapitulating downstream RET signaling pathways including AKT and ERK. It has been utilized in research to study epithelial morphogenesis and branching in kidney organoids, as well as a preclinical gene therapy candidate to alleviate Parkinson's disease progression by promoting dopaminergic neuronal survival and behavioral recovery in mouse models.

Other names: opto-RET

Beyond the preview

Go deeper on optoRET.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on optoRET.